liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting metastasis in paediatric bone sarcomas
Univ East Anglia, England.
Univ East Anglia, England; Amity Univ Haryana, India.
Univ East Anglia, England.
Univ East Anglia, England.
Show others and affiliations
2025 (English)In: Molecular Cancer, E-ISSN 1476-4598, Vol. 24, no 1, article id 153Article, review/survey (Refereed) Published
Abstract [en]

Paediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) comprise significant biological and clinical heterogeneity. This extreme heterogeneity affects response to systemic therapy, facilitates inherent and acquired drug resistance and possibly underpins the origins of metastatic disease, a key component implicit in cancer related death. Across all cancers, metastatic models have offered competing accounts on when dissemination occurs, either early or late during tumorigenesis, whether metastases at different foci arise independently and directly from the primary tumour or give rise to each other, i.e. metastases-to-metastases dissemination, and whether cell exchange occurs between synchronously growing lesions. Although it is probable that all the above mechanisms can lead to metastatic disease, clinical observations indicate that distinct modes of metastasis might predominate in different cancers. Around 70% of patients with bone sarcoma experience metastasis during their disease course but the fundamental molecular and cell mechanisms underlying spread are equivocal. Newer therapies such as tyrosine kinase inhibitors have shown promise in reducing metastatic relapse in trials, nonetheless, not all patients respond and 5-year overall survival remains at similar to 50%. Better understanding of potential bone sarcoma biological subgroups, the role of the tumour immune microenvironment, factors that promote metastasis and clinical biomarkers of prognosis and drug response are required to make progress. In this review, we provide a comprehensive overview of the approaches to manage paediatric patients with metastatic Ewing sarcoma and osteosarcoma. We describe the molecular basis of the tumour immune microenvironment, cell plasticity, circulating tumour cells and the development of the pre-metastatic niche, all required for successful distant colonisation. Finally, we discuss ongoing and upcoming patient clinical trials, biomarkers and gene regulatory networks amenable to the development of anti-metastasis medicines.

Place, publisher, year, edition, pages
BMC , 2025. Vol. 24, no 1, article id 153
Keywords [en]
Ewing sarcoma; Osteosarcoma; Bone; Sarcoma; Metastasis
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-214455DOI: 10.1186/s12943-025-02365-zISI: 001499302500001PubMedID: 40442778Scopus ID: 2-s2.0-105006883971OAI: oai:DiVA.org:liu-214455DiVA, id: diva2:1967030
Note

Funding Agencies|City of London Corporation through The Sir William Coxen Trust Fund; Children with Cancer UK; Children's Cancer and Leukaemia Group, Bone Cancer Research Trust; Richard Jenner Memorial Trust; Sophie's Sparkle Fund; Peter Stebbings Memorial Charity; Swedish Cancer Society; Swedish Childhood Cancer Fund; Swedish Research Council; AIRC Foundation for Cancer Research, Italian Ministry of Health; Swedish Foundation for Strategic Research, Austrian National Bank's Jubilumsfonds, Vienna Science and Technology Fund (WWTF); German Cancer Aid; German Child Cancer Foundation; Society for Pediatric Oncology and Hematology; Barbara and Wilfried Mohr Foundation; Cancer Grand Challenge program (PROTECT); European Union (ERC) [101122595]

Available from: 2025-06-11 Created: 2025-06-11 Last updated: 2025-09-22

Open Access in DiVA

fulltext(4072 kB)82 downloads
File information
File name FULLTEXT01.pdfFile size 4072 kBChecksum SHA-512
a870c20ea588f5af2f4e546df0485b60e0ced3373281b0e12ec1b2a9fcbaa521961fe37c5b0d1f5c4776618ceac1a18e0273be2481ed471f5f15cfbff876abce
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Velasco Riestra, PaulinaBojmar, LindaFahlgren, Anna
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesThe Division of Cell and Neurobiology
In the same journal
Molecular Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 82 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 117 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf